BTG, a global specialist healthcare company and Mirada Medical, a medical imaging software company, announced an important collaboration to develop dosimetry software solutions to optimise radioembolisation therapy with TheraSphere.
The companies are working together to provide a more personalised approach to radioembolisation for liver cancer patients, through easy-to-use and bespoke software that helps physicians plan the delivery of a specific radiation dose based on an individual patient’s need.
Peter Pattison, BTG General Manager Interventional Oncology, Commercial Operations commented "We are committed to providing patients and healthcare providers with value beyond just our products to improve outcomes for patients and ensure that our therapies are tailored to individual patient needs."
Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director commented "Our goal is to provide intuitive software that facilitates the clinician’s use of multi-modal images to plan radioembolisation therapy with the ultimate aim of leading to better patient outcomes. The collaboration with BTG leverages our image processing expertise and highlights the importance of imaging for planning treatments."
BTG and Mirada are excited to be on this journey together to offer interventional oncology teams more power to personalise and optimise radioembolisation therapy with TheraSphere®, for their patients.
The companies plan to make the software available in 2016.
BTG Interventional Medicine is part of BTG pl, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavours to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter.
TheraSphere Y glass microspheres are specifically engineered to carry far greater power than any other Y liver-directed cancer therapy, delivering high doses of radiation to liver tumours while sparing normal tissue.
The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.
In the EU, TheraSphere is CE Marked for the treatment of hepatic neoplasia. In the US, TheraSphere is FDA approved under a Humanitarian Device Exemption (HDE) for the treatment of hepatocellular carcinoma (HCC).